ZA201403760B - Anti-cd98 antibodies and methods of use thereof - Google Patents

Anti-cd98 antibodies and methods of use thereof

Info

Publication number
ZA201403760B
ZA201403760B ZA2014/03760A ZA201403760A ZA201403760B ZA 201403760 B ZA201403760 B ZA 201403760B ZA 2014/03760 A ZA2014/03760 A ZA 2014/03760A ZA 201403760 A ZA201403760 A ZA 201403760A ZA 201403760 B ZA201403760 B ZA 201403760B
Authority
ZA
South Africa
Prior art keywords
antibodies
methods
Prior art date
Application number
ZA2014/03760A
Inventor
Hoang Tran
Der Horst Edward Thein Htun Van
Joseph Zachwieja
John Lippincott
Original Assignee
Igenica Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenica Biotherapeutics Inc filed Critical Igenica Biotherapeutics Inc
Publication of ZA201403760B publication Critical patent/ZA201403760B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
ZA2014/03760A 2011-11-23 2014-05-22 Anti-cd98 antibodies and methods of use thereof ZA201403760B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161563443P 2011-11-23 2011-11-23
PCT/US2012/066347 WO2013078377A1 (en) 2011-11-23 2012-11-21 Anti-cd98 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
ZA201403760B true ZA201403760B (en) 2017-09-27

Family

ID=47295209

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/03760A ZA201403760B (en) 2011-11-23 2014-05-22 Anti-cd98 antibodies and methods of use thereof

Country Status (15)

Country Link
EP (1) EP2782935A1 (en)
JP (1) JP2015501639A (en)
KR (1) KR20140125351A (en)
CN (1) CN104302669A (en)
AU (1) AU2012340623A1 (en)
BR (1) BR112014012590A8 (en)
CA (1) CA2856873A1 (en)
HK (1) HK1202877A1 (en)
IL (1) IL232755A0 (en)
MX (1) MX2014006272A (en)
PH (1) PH12014501164A1 (en)
RU (1) RU2014124530A (en)
SG (1) SG11201402619VA (en)
WO (1) WO2013078377A1 (en)
ZA (1) ZA201403760B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3604339B1 (en) 2011-01-14 2021-03-10 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
US20140363454A1 (en) * 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
JP2017114763A (en) * 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
CN107207591A (en) * 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 Blood-brain barrier receptor antibody and application method
EP4005594A1 (en) * 2015-08-10 2022-06-01 Osaka University Antibody against cd98hc
CN105385694B (en) * 2015-11-20 2019-01-18 中国人民解放军第四军医大学 Anti-human CD98 monoclonal antibody 98-3H3 light and heavy chain variable region gene and its application
US20200121803A1 (en) * 2016-06-08 2020-04-23 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3468598A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-cd98 antibodies and antibody drug conjugates
RU2764651C2 (en) 2016-06-08 2022-01-19 Эббви Инк. Antibodies to b7-h3 and conjugates of antibody and drug
CN109562168A (en) * 2016-06-08 2019-04-02 艾伯维公司 Anti-CD 98 antibody and antibody drug conjugates
US20200399623A1 (en) 2018-02-07 2020-12-24 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
EP3715370A1 (en) * 2019-03-28 2020-09-30 Technische Universität München High affinity anticalins directed against human cd98hc
US20230174669A1 (en) * 2020-04-08 2023-06-08 Aliada Therapeutics, Inc. Anti-CD98 Antibodies And Uses Thereof
AR124681A1 (en) 2021-01-20 2023-04-26 Abbvie Inc ANTI-EGFR ANTIBODY-DRUG CONJUGATES
CN117561276A (en) * 2021-06-02 2024-02-13 华辉安健（北京）生物科技有限公司 anti-CD 98 antibodies and uses thereof
CN115772541A (en) * 2021-12-17 2023-03-10 百奥赛图江苏基因生物技术有限公司 Construction method and application of CD98HC gene humanized non-human animal

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (en) 1991-11-21 1993-06-16 Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
DE69233528T2 (en) 1991-11-25 2006-03-16 Enzon, Inc. Process for the preparation of multivalent antigen-binding proteins
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE199392T1 (en) 1992-12-04 2001-03-15 Medical Res Council MULTIVALENT AND MULTI-SPECIFIC BINDING PROTEINS, THEIR PRODUCTION AND USE
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
HU230769B1 (en) 1999-01-15 2018-03-28 Genentech Inc. Polypeptide variants with altred effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
ES2405551T3 (en) 2001-10-01 2013-05-31 Dyax Corporation Multicatenary eukaryotic presentation vectors and uses thereof
US20040005709A1 (en) 2001-10-24 2004-01-08 Hoogenboom Henricus Renerus Jacobus Mattheus Hybridization control of sequence variation
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ567140A (en) 2005-10-07 2011-09-30 Exelixis Inc Azetidines as MEK inhibitors for the treatment of proliferative diseases
TWI390034B (en) 2006-04-06 2013-03-21 Kyowa Hakko Kirin Co Ltd Novel anti-CD98 antibody
GB0615662D0 (en) * 2006-08-07 2006-09-13 Affitech As Antibody
EP2554552B1 (en) * 2010-03-26 2015-05-13 The University of Tokushima Novel anti-cd98 antibody and use thereof

Also Published As

Publication number Publication date
WO2013078377A9 (en) 2013-08-08
BR112014012590A8 (en) 2017-12-19
AU2012340623A1 (en) 2014-07-17
EP2782935A1 (en) 2014-10-01
NZ626513A (en) 2017-02-24
CN104302669A (en) 2015-01-21
PH12014501164A1 (en) 2014-10-20
HK1202877A1 (en) 2015-10-09
IL232755A0 (en) 2014-07-31
RU2014124530A (en) 2015-12-27
CA2856873A1 (en) 2013-05-30
BR112014012590A2 (en) 2017-06-20
WO2013078377A1 (en) 2013-05-30
JP2015501639A (en) 2015-01-19
MX2014006272A (en) 2014-10-24
KR20140125351A (en) 2014-10-28
SG11201402619VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
HK1255608A1 (en) Anti-htra1 antibodies and methods of use
HK1212256A1 (en) Anti-mcam antibodies and associated methods of use -mcam
HK1205517A1 (en) Anti sez6 antibodies and methods of use sez6
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
ZA201308022B (en) Anti-cd40 antibodies and methods of use
HK1201843A1 (en) Anti-polyubiquitin antibodies and methods of use
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
EP2670866A4 (en) Biomarkers and methods of use thereof
EP2771694A4 (en) Monoclonal antibodies and methods of use
HK1182117A1 (en) Anti-tenascin-c a2 antibodies and methods of use -c a2
EP2734234A4 (en) Anti-cxcr4 antibodies and methods of use
ZA201404675B (en) Anti-lrp5 antibodies and methods of use
EP2938632A4 (en) Anti-granulysin antibodies and methods of use thereof
EP2558496A4 (en) Anti-polyubiquitin antibodies and methods of use
HK1209432A1 (en) Anti-jagged antibodies and methods of use
ZA201300174B (en) Anti-neuropilin antibodies and methods of use
EP2663330A4 (en) Anti-tlr4 antibodies and methods of use thereof
HK1201537A1 (en) Anti-kdr antibodies and methods of use -kdr
EP2670436A4 (en) Foxc1 antibodies and methods of their use
HK1184173A1 (en) Anti-kdr antibodies and methods of use -kdr